Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction

Jung Youl Park, Jae Ho Chung, Hyung Chul Lee, Byung-Il Lee, Seung Ha Park, Eul Sik Yoon

Research output: Contribution to journalArticle

Abstract

Background Adjuvant therapy after breast surgery, including tamoxifen or aromatase inhibitors, improves the postoperative outcomes and long-term survival of breast cancer patients. The aim of this study was to determine whether volume changes occurred in the contralateral breast during hormonal or other adjuvant therapies. Methods This study reviewed 90 patients who underwent unilateral breast reconstruction between September 2012 and April 2018 using tissue expanders and a permanent implant after the surgical removal of breast cancer. The volume of the contralateral breast was measured using a cast before the first (tissue expander insertion) and second (permanent implant change) stages of surgery. Changes in breast volume were evaluated to determine whether adjuvant therapy such as hormonal therapy, chemotherapy, and radiation therapy influenced the volume of the contralateral breast. Results The group receiving tamoxifen therapy demonstrated a significant decrease in volume compared with the group without tamoxifen (−7.8% vs. 1.0%; P= 0.028). The aromatase inhibitor–treated group showed a significant increase in volume compared with those who did not receive therapy (−6.2% vs. 4.5%; P= 0.023). There were no significant differences between groups treated with other hormonal therapy, chemotherapy, or radiation therapy. Conclusions Patients who received tamoxifen therapy showed a significant decrease in volume in the contralateral breast, while no significant change in weight or body mass index was found. Our findings suggest that we should choose smaller implants for premenopausal patients, who have a high likelihood of receiving tamoxifen therapy.

Original languageEnglish
Pages (from-to)432-440
Number of pages9
JournalArchives of Plastic Surgery
Volume45
Issue number5
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Mammaplasty
Breast
Tamoxifen
Tissue Expansion Devices
Therapeutics
Radiotherapy
Breast Neoplasms
Drug Therapy
Aromatase Inhibitors
Aromatase
Body Mass Index
Weights and Measures
Survival

Keywords

  • Hormone antagonists
  • Mammaplasty
  • Reconstructive surgical procedures
  • Surgery, plastic
  • Tamoxifen

ASJC Scopus subject areas

  • Surgery

Cite this

Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction. / Park, Jung Youl; Chung, Jae Ho; Lee, Hyung Chul; Lee, Byung-Il; Park, Seung Ha; Yoon, Eul Sik.

In: Archives of Plastic Surgery, Vol. 45, No. 5, 01.09.2018, p. 432-440.

Research output: Contribution to journalArticle

@article{8494eb5999544d5c839b06eb187d2994,
title = "Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction",
abstract = "Background Adjuvant therapy after breast surgery, including tamoxifen or aromatase inhibitors, improves the postoperative outcomes and long-term survival of breast cancer patients. The aim of this study was to determine whether volume changes occurred in the contralateral breast during hormonal or other adjuvant therapies. Methods This study reviewed 90 patients who underwent unilateral breast reconstruction between September 2012 and April 2018 using tissue expanders and a permanent implant after the surgical removal of breast cancer. The volume of the contralateral breast was measured using a cast before the first (tissue expander insertion) and second (permanent implant change) stages of surgery. Changes in breast volume were evaluated to determine whether adjuvant therapy such as hormonal therapy, chemotherapy, and radiation therapy influenced the volume of the contralateral breast. Results The group receiving tamoxifen therapy demonstrated a significant decrease in volume compared with the group without tamoxifen (−7.8{\%} vs. 1.0{\%}; P= 0.028). The aromatase inhibitor–treated group showed a significant increase in volume compared with those who did not receive therapy (−6.2{\%} vs. 4.5{\%}; P= 0.023). There were no significant differences between groups treated with other hormonal therapy, chemotherapy, or radiation therapy. Conclusions Patients who received tamoxifen therapy showed a significant decrease in volume in the contralateral breast, while no significant change in weight or body mass index was found. Our findings suggest that we should choose smaller implants for premenopausal patients, who have a high likelihood of receiving tamoxifen therapy.",
keywords = "Hormone antagonists, Mammaplasty, Reconstructive surgical procedures, Surgery, plastic, Tamoxifen",
author = "Park, {Jung Youl} and Chung, {Jae Ho} and Lee, {Hyung Chul} and Byung-Il Lee and Park, {Seung Ha} and Yoon, {Eul Sik}",
year = "2018",
month = "9",
day = "1",
doi = "10.5999/aps.2018.00563",
language = "English",
volume = "45",
pages = "432--440",
journal = "Archives of Plastic Surgery",
issn = "2234-6163",
publisher = "Korean Society of Plastic and Reconstructive Surgeons",
number = "5",

}

TY - JOUR

T1 - Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction

AU - Park, Jung Youl

AU - Chung, Jae Ho

AU - Lee, Hyung Chul

AU - Lee, Byung-Il

AU - Park, Seung Ha

AU - Yoon, Eul Sik

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background Adjuvant therapy after breast surgery, including tamoxifen or aromatase inhibitors, improves the postoperative outcomes and long-term survival of breast cancer patients. The aim of this study was to determine whether volume changes occurred in the contralateral breast during hormonal or other adjuvant therapies. Methods This study reviewed 90 patients who underwent unilateral breast reconstruction between September 2012 and April 2018 using tissue expanders and a permanent implant after the surgical removal of breast cancer. The volume of the contralateral breast was measured using a cast before the first (tissue expander insertion) and second (permanent implant change) stages of surgery. Changes in breast volume were evaluated to determine whether adjuvant therapy such as hormonal therapy, chemotherapy, and radiation therapy influenced the volume of the contralateral breast. Results The group receiving tamoxifen therapy demonstrated a significant decrease in volume compared with the group without tamoxifen (−7.8% vs. 1.0%; P= 0.028). The aromatase inhibitor–treated group showed a significant increase in volume compared with those who did not receive therapy (−6.2% vs. 4.5%; P= 0.023). There were no significant differences between groups treated with other hormonal therapy, chemotherapy, or radiation therapy. Conclusions Patients who received tamoxifen therapy showed a significant decrease in volume in the contralateral breast, while no significant change in weight or body mass index was found. Our findings suggest that we should choose smaller implants for premenopausal patients, who have a high likelihood of receiving tamoxifen therapy.

AB - Background Adjuvant therapy after breast surgery, including tamoxifen or aromatase inhibitors, improves the postoperative outcomes and long-term survival of breast cancer patients. The aim of this study was to determine whether volume changes occurred in the contralateral breast during hormonal or other adjuvant therapies. Methods This study reviewed 90 patients who underwent unilateral breast reconstruction between September 2012 and April 2018 using tissue expanders and a permanent implant after the surgical removal of breast cancer. The volume of the contralateral breast was measured using a cast before the first (tissue expander insertion) and second (permanent implant change) stages of surgery. Changes in breast volume were evaluated to determine whether adjuvant therapy such as hormonal therapy, chemotherapy, and radiation therapy influenced the volume of the contralateral breast. Results The group receiving tamoxifen therapy demonstrated a significant decrease in volume compared with the group without tamoxifen (−7.8% vs. 1.0%; P= 0.028). The aromatase inhibitor–treated group showed a significant increase in volume compared with those who did not receive therapy (−6.2% vs. 4.5%; P= 0.023). There were no significant differences between groups treated with other hormonal therapy, chemotherapy, or radiation therapy. Conclusions Patients who received tamoxifen therapy showed a significant decrease in volume in the contralateral breast, while no significant change in weight or body mass index was found. Our findings suggest that we should choose smaller implants for premenopausal patients, who have a high likelihood of receiving tamoxifen therapy.

KW - Hormone antagonists

KW - Mammaplasty

KW - Reconstructive surgical procedures

KW - Surgery, plastic

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85056471233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056471233&partnerID=8YFLogxK

U2 - 10.5999/aps.2018.00563

DO - 10.5999/aps.2018.00563

M3 - Article

VL - 45

SP - 432

EP - 440

JO - Archives of Plastic Surgery

JF - Archives of Plastic Surgery

SN - 2234-6163

IS - 5

ER -